Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Metabolomische und Darmmikrobenbiomarker für die Behandlung von Raucherentwöhnung in der Langzeitmedikamententherapie: Eine randomisierte kontrollierte Studie

28. September 2026 aktualisiert von: Sigmund Freud PrivatUniversitat

Theoretical Framework: Cigarette smoking is the leading preventable cause of death worldwide, with nicotine dependence notably common among individuals with Substance Use Disorders (SUD). Smoking exacerbates both physical and mental health issues, further complicating the treatment of SUD. Current therapeutic approaches for SUD often prove inadequate, indicating a need for new strategies. Recent advancements in metabolomics and gut microbiome research have provided valuable insights into the biological mechanisms underlying addiction.

Objectives: This study aims to investigate the therapeutic potential of smoking cessation for individuals with SUD, using a six-week intervention within a therapeutic community. The research specifically explores the psychobehavioral, metabolic, and gut microbiome domains. It is hypothesized that smoking cessation will improve emotional regulation, self-efficacy, and reduce substance craving, mediated by changes in metabolic and microbiome profiles linked to brain reward systems.

Methods: A randomized controlled trial (N=150) will be conducted, examining outcomes such as clinical relapse rates, microbial and metabolic markers, particularly in choline and folate metabolism. Participants with SUD (n=100) will undergo a six-week smoking cessation intervention, with pre- and post-assessments, compared to a control group receiving treatment as usual. Metabolomic and microbiome analyses will be conducted using blood and stool samples, alongside psychological assessments via questionnaires. Assessments on a behavioural level will take place at a 3-months follow-up.

A cross-sectional, non-interventional healthy control group (n=50) will be examined at a single timepoint with an anologous panel of psychological variables, blood and stool to ascertain differences between smokers with SUD and healthy controls.

Studienübersicht

Studientyp

Interventionell

Einschreibung (Tatsächlich)

97

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Fehring, Österreich, 8350
        • Grüner Kreis Organization Johnsdorf Facility
      • Graz, Österreich, 8036
        • Medical University Graz
      • Vienna, Österreich, 1020
        • Sigmund Freud Private University Vienna

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • diagnosis of a form of substance use disorder (F1x.x) by a licensed psychiatrist according to ICD-10
  • minimum age of 18 years
  • sufficient knowledge of the German language
  • willingness to quit smoking
  • willingness and ability to consent

Inclusion criteria for healthy controls :

  • minimum age of 18 years
  • sufficient knowledge of the German language
  • willingness and ability to consent

Exclusion Criteria:

  • lack of consent, inability to provide informed consent
  • age below 18,
  • acute psychotic symptoms or acute suicidal tendencies
  • cardiovascular disease
  • pregnancy or breastfeeding
  • severe mental or organic illnesses (such as epilepsy, brain tumors, recent major surgery), tumor diseases, dementia (Mini Mental Score <20), severe autoimmune diseases or immunosuppression, acute infections, or acute diarrhea, prior gastrointestinal surgery (except appendectomy)
  • probiotic intake within the last 6 months,
  • ongoing consumtion of dietary supplements, probiotics, antibiotics, or prebiotic supplements during the study
  • prior participation in a smoking cessation programme

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Treatment As Usual

Patients in the TAU group receive long-term rehabilitation drug treatment according to the 'community as a treatment'-model

The standard treatment within the 'Grüner Kreis' therapeutic community - which all participants will receive - consists of group therapy (once a week), individual psychotherapy (once a week), counselling by social workers, psychiatric consultations, as well as sport-, art- and work-therapy. Daily life is organized according to principles of therapeutic community-based addiction treatment.

Experimental: 6-weeks smoking cessation cognitive-behavioral therapy intervention

The "smoke free in 6 weeks" program is a standardized behavioural therapy intervention that takes place once a week for 1.5 hours over 6 weeks and is provided by the Austrian health insurance provider Österreichische Gesundheitskasse (ÖGK).

The standard treatment within the 'Grüner Kreis' therapeutic community - which all participants will receive - consists of group therapy (once a week), individual psychotherapy (once a week), counselling by social workers, psychiatric consultations, as well as sport-, art- and work-therapy. Daily life is organized according to principles of therapeutic community-based addiction treatment.

Held in the therapeutic community, the intervention will employ principles of cognitive-behavioural therapy (CBT) coupled with personalized recommendations for nicotine replacement. The Austrian Health Insurance standard for therapy will be guiding the program's content, which is tailored for inpatient clients. Specifically, the following interventions based on CBT techniques will be applied in the weekly group sessions consisting of 10 to 15 participants: Psychoeducation including information on tobacco addiction, health risks, advice on relapse prevention and the handling of craving, motivation building, behavioural observation.

Kein Eingriff: Healthy controls

Control group with n=50 healthy adult subjects, examined at a single timepoint. No interventions will be administered in this arm.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Self-efficacy
Zeitfenster: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period

Self-efficacy as a psychological variable and will be assessed by the Self-Efficacy Scale (SWE), a self-report instrument for measuring general optimistic self-confidence. It consists of 10 items and measures optimistic competence expectancy, i.e., confidence in solving difficult situations with one's own abilities.

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period
General substance-related craving
Zeitfenster: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Substance related craving will be assessed by the MaCS (Mannheim Craving Scale). consists of 12 items and four additional items and is rated on a 5- point Likert scale.

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
Tobacco dependence
Zeitfenster: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Tobacco dependence will be assessed by The Fagerström Test for Cigarette Dependence (formerly Fagerström Test for Nicotine Dependence; FTND). It consists of 6 categorically scaled items that assess the number of smoked cigarettes per day (CPD), compulsive use, and dependence intensity.

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
Primary Affects
Zeitfenster: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Primary Affects, as proposed by Jaak Panksepp will be assessed by the German Version of the Brief Affective Neuroscience Personality Scales including a LUST Scale (BANPS-GL), a self-report questionnaire.

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
Metabolome
Zeitfenster: From enrollment to the end of the 6-weeks treatment period.

Metabolome will be ascertained from blood via state-of-the-art NMR (nuclear magnetic resonance).

From enrollment to the end of the 6-weeks treatment period.
Gut microbiome
Zeitfenster: From enrollment to the end of the 6-weeks treatment period.

Gut microbiome will be ascertained via 16s-rRNA sequencing from stool.

From enrollment to the end of the 6-weeks treatment period.
Smoking behaviour
Zeitfenster: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Participants will be asked regarding their daily smoked cigarettes in the last two weeks (interval scaled). A second single item question will be, if participants have been completely abstinent from tobacco smoking in the last two weeks (dichotome).

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Psychiatric Symptoms
Zeitfenster: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

For the evaluation of psychopathology, the ICD-10 Symptom Rating (ISR) questionnaire will be utilized. In accordance with the ICD-10, this self-assessment questionnaire, comprising 30 items, is designed to comprehensively assess the status and severity of mental disturbances. Symptoms of the six symptomatic patterns - depressive, anxiety, obsessive-compulsive, eating disorders, somatoform syndrome, and post-traumatic stress disorder - are assessed.

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

5. Mai 2025

Primärer Abschluss (Tatsächlich)

18. September 2026

Studienabschluss (Tatsächlich)

18. September 2026

Studienanmeldedaten

Zuerst eingereicht

23. Januar 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

27. Januar 2025

Zuerst gepostet (Tatsächlich)

31. Januar 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

29. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

28. September 2026

Zuletzt verifiziert

1. März 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 1155/2024
  • 1155/2024 (Andere Kennung: Ethikkommission der Medizinischen Universität Graz)

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren